Memory Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Memory Pharmaceuticals
Starting stock price: $2.69
Ending stock price: $0.56
Percent Change: -79.18%

Details: In March of 2007, Memory's stock took a hit after researchers announced that its lead drug--MEM 1003--failed to achieve any of its endpoints in a mid-stage study for mania in bipolar patients. Results of the same drug as a therapy for Alzheimer's were no better, and the company's stock suffered another major hit in October when MEM 1003 fell short in demonstrating a statistically significant response for improved symptoms after 12 weeks.  

More News:
Memory's Alzheimer's drug aces Phase II. Report
Memory's Alzheimer's drug flunks Phase II. Report
Memory shares plunge as lead drug fails trial. Report

Memory Pharmaceuticals - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.

Several of GlaxoSmithKline's vaccines are riding strong momentum and now the drugmaker is selling two assets to focus on those growth products.